Clinical trials: Costs
Benign Prostatic Hyperplasia
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
In patients with benign prostatic hyperplasia (BPH), combination therapy with an alpha-blocker (AB) and a 5 alpha-reductase inhibitor (5ARI) has been shown to reduce the progression of acute urinary retention (AUR) and the…
- Trial name
- NCT01435954
- Testing
- Early combination therapy, Delayed combination therapy
- Volunteers
- 13,551 people
- Sponsor
- GlaxoSmithKline